Kadmon, Jinghua enter mAb deal

Kadmon Corp. LLC (New York, N.Y.) said it granted Jinghua Pharmaceutical Co. Ltd. (Nantong, China) an exclusive license to develop and commercialize Kadmon's human mAbs against VEGF receptor 2 ( VEGFR-2; KDR/Flk-1) and PD-L1 in Greater China. Jinghua also licensed Kadmon's technology to discover and develop additional human mAbs in China. ...